Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable G protein-coupled receptor 33 (GPR33) is a member of the rhodopsin-like (class A) G protein-coupled receptor (GPCR) superfamily, sharing the typical seven-transmembrane domain architecture common to this group[1][3]. However, in humans and some other species, GPR33 is classified as a pseudogene, meaning it is a non-functional gene that does not produce an active protein product. As such, it does not function as a therapeutic target nor is it involved in physiological GPCR-mediated processes in humans. There are no known approved or experimental drugs or ligands that interact with GPR33, nor are there validated roles as a disease biomarker or in therapy monitoring. It is sometimes discussed in the context of evolutionary genomic studies due to its pseudogenization in humans, but it does not represent a viable molecular target for pharmacological intervention. Notes and context: GPR33 was originally annotated as a receptor, but subsequent research has established that it is a pseudogene in humans, lacking a functional open reading frame and therefore not encoding a working receptor protein. As a member of the GPCR family, if GPR33 were functional, it would be expected to play a role in signal transduction, as does the rest of the family [1][3], but this is not the case in humans due to its pseudogene status. There are no documented interacting drugs, documented clinical biomarkers, or safety/therapeutic challenges related to GPR33 because it is not expressed as a functional protein in humans. Summary: GPR33 does not constitute an active therapeutic target in humans due to its characterization as a pseudogene; no pharmacological or clinical information is associated with it. Thus, is_target = false and is_incorrect = true (the target is not therapeutically relevant in humans, though the naming and pseudogene status may cause confusion).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable G protein-coupled receptor 33 (GPR33).